Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature.
Katarzyna Konieczka, Simone Koch, Daniela Hauenstein, Thomas Navin Chackathayil, Tatjana Binggeli, Andreas Schoetzau, Josef Flammer
Summary
Brimonidine, but not latanoprost, had a significant effect on central CT.
Abstract
PURPOSE
The aim of this study was to investigate the effects of the glaucoma drugs latanoprost, brimonidine, and the combination of both on the central corneal temperature (CT) of healthy subjects by means of infrared thermography. Changes of the central CT may reflect changes of ocular blood flow.
METHODS
Before application and during 2 hours after the application of latanoprost, brimonidine, or the combination of both in one eye, the CT in both eyes of 40 healthy subjects was measured repeatedly.
RESULTS
Brimonidine reduced CT by approximately 0.5°C. This effect was statistically significant (< 0.0001). Latanoprost, however, had a very small and insignificant influence (= 0.47). Accordingly, the combination of brimonidine and latanoprost also reduced CT up to 0.5°C, and this effect was statistically significant (< 0.0001).
CONCLUSIONS
Brimonidine, but not latanoprost, had a significant effect on central CT. This cooling effect of brimonidine is most probably due to a drug-induced reduction of blood circulation in the ciliary body and iris and to a certain extent also to a reduction of blood flow in the fundus of the eye.
TRANSLATIONAL RELEVANCE
This study shows evidence that thermography of the cornea provides indirect information on the influence of drugs on the blood flow to the anterior segment of the patient's eye.
Keywords
More by Katarzyna Konieczka
View full profile →Top Research in IOP & Medical Therapy
Browse all →The Complications of Myopia: A Review and Meta-Analysis.
Inflammation in Glaucoma: From the back to the front of the eye, and beyond.
Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up.
In the Knowledge Library
Discussion
Comments and discussion will appear here in a future update.